Prostatic asymmetry as a risk factor for prostatic carcinoma

Serial prostate-specific antigen monitoring and cancer detection

J. G. Hansen, B. L. Dalkin, C. H. Harris, C. S. Johnson, Frederick R Ahmann

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. To compare the rates of cancer detection in men with a normal, asymmetric, or suspicious prostate on digital rectal examination (DRE) initially and after 3 years of serial monitoring of prostate specific antigen (PSA) level. Patients and methods. Prostatic 'asymmetry' was defined as asymmetric growth of the lateral lobes of the prostate without induration or nodules, as assessed by a DRE. The study included 963 men with no clinical evidence of prostate cancer and whose serum PSA levels were monitored at 4 month intervals. Prostatic biopsy was recommended if the PSA level became persistently abnormal (> 4 ng/mL) or increased by > 20% after having been initially abnormal. Cancer detection rates were compared among groups categorized by the initial DRE findings and serum PSA level. Results. On comparing groups with suspicious and normal DREs, and abnormal with normal PSA levels both, as expected, were associated with a statistically significant increase in cancer detection. However, an asymmetric prostate did not carry an increased risk of detecting prostate cancer when compared with a normal prostate, regardless of PSA level. Conclusions. An asymmetric prostate does not appear to be an independent risk factor for detecting prostate cancer. Therefore, an asymmetric prostate with no abnormality in PSA level should not mandate prostatic biopsy, or even an increase in monitoring frequency above the presently recommended annual interval.

Original languageEnglish (US)
Pages (from-to)924-926
Number of pages3
JournalBritish Journal of Urology
Volume79
Issue number6
StatePublished - 1997

Fingerprint

Prostate-Specific Antigen
Prostate
Carcinoma
Digital Rectal Examination
Neoplasms
Prostatic Neoplasms
Biopsy
Serum
Growth

Keywords

  • Asymmetry
  • Digital rectal examination
  • Prostate cancer
  • Prostate specific antigen

ASJC Scopus subject areas

  • Urology

Cite this

Prostatic asymmetry as a risk factor for prostatic carcinoma : Serial prostate-specific antigen monitoring and cancer detection. / Hansen, J. G.; Dalkin, B. L.; Harris, C. H.; Johnson, C. S.; Ahmann, Frederick R.

In: British Journal of Urology, Vol. 79, No. 6, 1997, p. 924-926.

Research output: Contribution to journalArticle

@article{8aac04714566493cbb0715f94dc806c6,
title = "Prostatic asymmetry as a risk factor for prostatic carcinoma: Serial prostate-specific antigen monitoring and cancer detection",
abstract = "Objective. To compare the rates of cancer detection in men with a normal, asymmetric, or suspicious prostate on digital rectal examination (DRE) initially and after 3 years of serial monitoring of prostate specific antigen (PSA) level. Patients and methods. Prostatic 'asymmetry' was defined as asymmetric growth of the lateral lobes of the prostate without induration or nodules, as assessed by a DRE. The study included 963 men with no clinical evidence of prostate cancer and whose serum PSA levels were monitored at 4 month intervals. Prostatic biopsy was recommended if the PSA level became persistently abnormal (> 4 ng/mL) or increased by > 20{\%} after having been initially abnormal. Cancer detection rates were compared among groups categorized by the initial DRE findings and serum PSA level. Results. On comparing groups with suspicious and normal DREs, and abnormal with normal PSA levels both, as expected, were associated with a statistically significant increase in cancer detection. However, an asymmetric prostate did not carry an increased risk of detecting prostate cancer when compared with a normal prostate, regardless of PSA level. Conclusions. An asymmetric prostate does not appear to be an independent risk factor for detecting prostate cancer. Therefore, an asymmetric prostate with no abnormality in PSA level should not mandate prostatic biopsy, or even an increase in monitoring frequency above the presently recommended annual interval.",
keywords = "Asymmetry, Digital rectal examination, Prostate cancer, Prostate specific antigen",
author = "Hansen, {J. G.} and Dalkin, {B. L.} and Harris, {C. H.} and Johnson, {C. S.} and Ahmann, {Frederick R}",
year = "1997",
language = "English (US)",
volume = "79",
pages = "924--926",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Prostatic asymmetry as a risk factor for prostatic carcinoma

T2 - Serial prostate-specific antigen monitoring and cancer detection

AU - Hansen, J. G.

AU - Dalkin, B. L.

AU - Harris, C. H.

AU - Johnson, C. S.

AU - Ahmann, Frederick R

PY - 1997

Y1 - 1997

N2 - Objective. To compare the rates of cancer detection in men with a normal, asymmetric, or suspicious prostate on digital rectal examination (DRE) initially and after 3 years of serial monitoring of prostate specific antigen (PSA) level. Patients and methods. Prostatic 'asymmetry' was defined as asymmetric growth of the lateral lobes of the prostate without induration or nodules, as assessed by a DRE. The study included 963 men with no clinical evidence of prostate cancer and whose serum PSA levels were monitored at 4 month intervals. Prostatic biopsy was recommended if the PSA level became persistently abnormal (> 4 ng/mL) or increased by > 20% after having been initially abnormal. Cancer detection rates were compared among groups categorized by the initial DRE findings and serum PSA level. Results. On comparing groups with suspicious and normal DREs, and abnormal with normal PSA levels both, as expected, were associated with a statistically significant increase in cancer detection. However, an asymmetric prostate did not carry an increased risk of detecting prostate cancer when compared with a normal prostate, regardless of PSA level. Conclusions. An asymmetric prostate does not appear to be an independent risk factor for detecting prostate cancer. Therefore, an asymmetric prostate with no abnormality in PSA level should not mandate prostatic biopsy, or even an increase in monitoring frequency above the presently recommended annual interval.

AB - Objective. To compare the rates of cancer detection in men with a normal, asymmetric, or suspicious prostate on digital rectal examination (DRE) initially and after 3 years of serial monitoring of prostate specific antigen (PSA) level. Patients and methods. Prostatic 'asymmetry' was defined as asymmetric growth of the lateral lobes of the prostate without induration or nodules, as assessed by a DRE. The study included 963 men with no clinical evidence of prostate cancer and whose serum PSA levels were monitored at 4 month intervals. Prostatic biopsy was recommended if the PSA level became persistently abnormal (> 4 ng/mL) or increased by > 20% after having been initially abnormal. Cancer detection rates were compared among groups categorized by the initial DRE findings and serum PSA level. Results. On comparing groups with suspicious and normal DREs, and abnormal with normal PSA levels both, as expected, were associated with a statistically significant increase in cancer detection. However, an asymmetric prostate did not carry an increased risk of detecting prostate cancer when compared with a normal prostate, regardless of PSA level. Conclusions. An asymmetric prostate does not appear to be an independent risk factor for detecting prostate cancer. Therefore, an asymmetric prostate with no abnormality in PSA level should not mandate prostatic biopsy, or even an increase in monitoring frequency above the presently recommended annual interval.

KW - Asymmetry

KW - Digital rectal examination

KW - Prostate cancer

KW - Prostate specific antigen

UR - http://www.scopus.com/inward/record.url?scp=0031400568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031400568&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 924

EP - 926

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -